3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase NA
1
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Promyelocytic, Acute
7
Leukemia
3
Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Childhood Acute Promyelocytic Leukemia With PML-RARA
1
Interventions
Paclitaxel
20
Gemcitabine
16
Dexamethasone
16
Bevacizumab
16
Docetaxel
15
Oxaliplatin
14
Cyclophosphamide
13
Carboplatin
12
Capecitabine
12
Sorafenib
11
Fluorouracil
11
Leucovorin
10
Cisplatin
10
pembrolizumab
9
Prednisone
9
Pemetrexed
9
Epoetin Alfa
9
venetoclax
8
atezolizumab
8
Fentanyl
8
Drug Therapy
8
Doxorubicin
8
Rivaroxaban
7
Rituximab
7
Darbepoetin alfa
7
Anastrozole
7
Panitumumab
6
Ondansetron
6
Morphine
6
Irinotecan
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms
×
Arsenic Trioxide
×
Clear all
NCT07504458
2026-04-16
QUATRO-APL
Quetzal Therapeutics
Phase 3
Recruiting
150 enrolled